Clinical trial
An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial…
NCT00235300 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00235300 |
|---|---|
| Title | An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients. |
| Official title | An Open-Label Prospective, Randomized, Multicenter Phase II Comparative Trial of Thymoglobulin® Versus Simulect® for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cadaveric Donor Renal Transplantation, Acute Renal Allograft Rejection, Induction Therapy |
| Intervention type | Biological, Drug |
| Interventions | Thymoglobulin [Anti-thymocyte Globulin (rabbit)], Simulect (basliximab) |
| Enrollment | 240 |
| Start date | May 1, 2000 |
| Primary completion | Apr 1, 2003 |
| Completion | Jun 1, 2005 |
| First posted | Oct 10, 2005 |
| Last update posted | Mar 18, 2015 |
| Countries | France, Germany, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: